Listed by the USPTO as ORWIG, KEVIN S
Tech Center 3900 • Art Units: 1611 1658 3991
This examiner grants 26% of resolved cases
ORWIG, KEVIN S is assigned to Tech Center 3900 and Art Unit 1611. The record covers 714 resolved cases, with an allowance rate of 25.5%. The median time to allowance is 1534 days, while the interview lift is 40.1%. Together, these figures show a prosecution record with a positive association between interviews and allowance outcomes, alongside a lengthy median path to allowance.
The listed companies are Creative Bio-Peptides Inc., Inhibikase Therapeutics Inc., and The Board of Trustees of the Leland Stanford Junior University. The listed firms are POLSINELLI PC (Main Customer Number), Clark+Elbing LLP, and FENWICK & WEST LLP. Practitioners working in this docket may consider interview preparation as part of amendment and response planning, while accounting for the reported prosecution duration.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18894338 | COMPOSITIONS AND METHODS FOR INHIBITING KINASES | Non-Final OA | Inhibikase Therapeutics, Inc. |
| 18320145 | TUMOR-SPECIFIC MINICIRCLES FOR CANCER SCREENING | Non-Final OA | The Board of Trustees of the Leland Stanford Junior University |
| 18711216 | GLUCOSE-RESPONSIVE INSULIN CONJUGATES COMPRISING A TETRA-VALENT SUGAR CLUSTER FOR TREATMENT OF DIABETES | Non-Final OA | Merck Sharp & Dohme LLC |
| 19213362 | Use of an All-D-Pentapeptide Chemokine Antagonist to Reduce Opioid Dose in a Person with Pain | Non-Final OA | Creative Bio-Peptides, Inc. |
| 17869925 | USE OF AN ALL-D-PENTAPEPTIDE CHEMOKINE ANTAGONIST TO REDUCE OPIOID DOSE IN A PERSON WITH PAIN | Final Rejection | Creative Bio-Peptides Inc. |
| 18282152 | REVERSAL OF CTL EXHAUSTION WITH ANNEXIN V | Non-Final OA | ERASMUS UNIVERSITY MEDICAL CENTER ROTTERDAM |
| 18662935 | COMBINATIONS AND METHODS FOR SUBCUTANEOUS ADMINISTRATION OF IMMUNE GLOBULIN AND HYALURONIDASE | Non-Final OA | Takeda Pharmaceutical Company Limited |
| 18760979 | HUMANISED ANTIBODIES | Non-Final OA | UCB Biopharma SRL |
| 18669075 | BIOMARKERS AND METHODS FOR DETECTION OF SEIZURES AND EPILEPSY | Non-Final OA | Cognizance Biomarkers, Inc. |
| 18653842 | COMPOSITIONS AND METHODS FOR INHIBITING GENE EXPRESSION OF HEPATITIS B VIRUS | Non-Final OA | Arrowhead Pharmaceuticals, Inc. |
| 18698649 | Biologically Active Collagen Hybridizing Peptides | Non-Final OA | 3HELIX, INC. |
| 18574406 | PEPTIDE HAVING ANTIDIABETIC ACTIVITY AND USE THEREOF | Final Rejection | MEDI&GENE INC. |
| 18530761 | METHODS TO GENERATE GASTROINTESTINAL EPITHELIAL TISSUE CONSTRUCTS | Final Rejection | The University of North Carolina at Chapel Hil |
| 17819591 | PREPARATION AND COMPOSITION OF INTER-ALPHA INHIBITOR PROTEINS FROM HUMAN PLASMA FOR THERAPEUTIC USE | Non-Final OA | ProThera Biologics, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy25.5% of resolved applications examined by Kevin S Orwig were allowed (714 resolved cases), compared with 35.0% across Art Unit 1611 over the last five years.
This examiner's interview lift is +40.1 percentage points: the difference in allowance rate between resolved applications that had an examiner interview and those that did not.
Applications allowed by Kevin S Orwig took 1,534 days on average from filing to allowance.
Kevin S Orwig examines applications in Art Unit 1611 in Tech Center 3900.
